Shanghai-based asset manager Yingke PE has set up two new funds with a total target corpus of 1 billion yuan ($156.8 million) as it seeks to expand its portfolio of almost 300 biopharmaceutical and hard tech companies.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
